AstraZeneca and other UK pharma boosted by Trump's first drug discount deal with Pfizer

President Trump's administration has secured its first 'most favored nation' drug discount deal with Pfizer, which will offer average discounts of 50% on many prescription drugs in exchange for a three-year tariff exemption and expanded U.S. manufacturing investment. This agreement led to a 6.8% surge in Pfizer shares and significant gains across the broader pharmaceutical sector, including major UK drugmakers like AstraZeneca, as the administration signals ongoing negotiations with other companies under threat of potential tariffs.

Analysis

The US government's first drug discount agreement with Pfizer has catalyzed a significant rally across the pharmaceutical sector, alleviating near-term pricing and tariff uncertainty. Pfizer's stock surged 6.8% after it agreed to offer average discounts of 50% on a majority of its primary care drugs in exchange for a three-year exemption from potential tariffs, contingent on increased US-based investment. This development is being interpreted as a positive precedent for the industry, evidenced by the broad-based rally that lifted UK drugmakers, including a 4% jump for Hikma Pharmaceuticals and a 3.6% rise for AstraZeneca, as well as US peers like Merck and Eli Lilly, which gained over 3%. The agreement establishes a clear framework for other companies, which now face the prospect of a 5-8% tariff if they do not reach similar accords. While the steep discounts will impact future revenues, the market is currently prioritizing the clarity on pricing and the removal of tariff risk, viewing this as a net positive that enhances the sector's operational stability.

Key Decisions for Investors

• The Pfizer agreement substantially de-risks the pharmaceutical sector from US tariff and pricing policy overhang, suggesting a more favorable investment environment for large-cap pharma companies with significant American market exposure.
• Investors should monitor upcoming negotiations with other major drugmakers, as the terms of their deals will be critical in determining the true economic trade-off between margin compression from discounts and the benefit of tariff avoidance.
• While Pfizer secured a first-mover advantage, the strong positive reaction in UK-listed stocks like AstraZeneca and GSK indicates that the market anticipates a sector-wide resolution, warranting a review of positions in European pharma to capitalize on this policy shift.